In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Heart failure (HF) prevalence remains high worldwide with significant sex-related and
regional differences in its presentation, management, and outcomes. In 2020, advances in …

Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …

Aims Blood uric acid (UA) levels are frequently elevated in patients with heart failure and
reduced ejection fraction (HFrEF), may lead to gout and are associated with worse …

Background An association between uric acid (UA) and cardiovascular diseases, including
heart failure (HF), has been reported. However, whether UA is a causal risk factor for HF is …

Introduction Serum uric acid (SUA) has been depicted as a contributory causal factor in
metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim We …

Angiotensin receptor-neprilysin inhibitors (ARNIs) are a new class of cardiovascular agents
characterized by their dual action on the major regulators of the cardiovascular system …

High serum uric acid (SUA) and triglyceride (TG) levels might promote high-cardiovascular
risk phenotypes across the cardiometabolic spectrum. However, SUA predictive power in the …

Angiotensin receptor–neprilysin inhibitors have multiple beneficial effects on the
cardiovascular system. The angiotensin receptor–neprilysin inhibitor sacubitril/valsartan has …

Aims This systematic review and meta‐analysis aimed to investigate the association
between serum uric acid (SUA) levels and the incidence rate and prognosis of heart failure …